Veracyte Publishes Data Supporting Clinical Use of Percepta Lung Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb) — Veracyte and a team of academic collaborators reported yesterday clinical data showing that the company's microarray-based Percepta Bronchial Genomic Classifier, which uses a 23-gene panel to identify patients at low risk of cancer following an inconclusive bronchoscopy result, may help prevent unnecessary invasive procedures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.